Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on July 1, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 contains Perspective Therapeutics’ corporate presentation.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Exhibit 99.1 contains Perspective Therapeutics’ corporate presentation
- Filing dated July 1, 2026 and signed by CFO Joel Sendek
- Investor-relevant operating and strategic details are contained in the referenced presentation
Item EX-99.1 · Exhibit EX-99.1
- Investor presentation outlines Perspective’s ²¹²Pb radiopharmaceutical platform, integrated isotope production, and regional direct-to-hospital delivery model
- VMT-α-NET Phase 1/2a data highlight deepening responses and durable disease control in SSTR2-positive neuroendocrine tumors
- VMT-α-NET safety analysis covers 68 treated patients, supporting potential registration study at the current dose
- VMT01 and PSV359 expand the pipeline into MC1R-targeted melanoma and FAP-α solid tumors
- Presentation supports further development but remains early-stage clinical evidence, with no definitive efficacy or approval outcome disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.